CD19+ EVs formed from B cells are rich in CD39 and CD73 vesicle fusion proteins, which can hydrolyse ATP produced by chemotherapy‐induced tumour cells to adenosine, limit CD8+ T‐cell proliferation and anti‐tumour actions, and therefore reduce the efficacy of chemotherapy. The gene discussed is CD8A; the disease is neoplasm.